-
Diagnostic Pathology Jun 2024Intravascular papillary endothelial hyperplasia (IPEH) represents an uncommon reactive endothelial hyperplastic proliferation. A 46-year-old man experienced increased... (Review)
Review
Intravascular papillary endothelial hyperplasia (IPEH) represents an uncommon reactive endothelial hyperplastic proliferation. A 46-year-old man experienced increased volume in the right maxilla, elevation of the nasal ala, and swelling of the hard palate with a reddish hue for 3 months. Computed tomography revealed an expansive hypodense region and cortical bone destruction associated with an impacted supernumerary tooth and an endodontically treated tooth. Under the differential diagnoses of a radicular cyst, dentigerous cyst, and ameloblastoma, an exploratory aspiration and incisional biopsy were performed. This revealed the formation of blood vessels of various diameters lined by endothelium, forming intravascular papillae positive for CD-34. The definitive diagnosis was IPEH, and the patient was treated by embolization and surgery. Histological analysis confirmed the presence of IPEH associated with an odontogenic cyst. After 12 months of follow-up, no recurrence was observed. Also, we reviewed case reports of IPEH affecting the maxilla and mandible. Fourteen intraosseous cases were reported in the maxilla and mandible, with a preference for males and affecting a wide age range. Complete surgical excision was the treatment of choice, and recurrences were not reported. The pathogenesis of IPEH is controversial and may originate from trauma or inflammatory processes. To the best of our knowledge, this is the first report of an association of IPEH with an odontogenic cyst. The importance of IPEH in the differential diagnosis of intraosseous lesions in the jaws is emphasized, and preoperative semiotic maneuvers are needed to prevent surgical complications.
Topics: Humans; Male; Middle Aged; Odontogenic Cysts; Hyperplasia; Diagnosis, Differential; Maxilla; Biopsy; Treatment Outcome; Tomography, X-Ray Computed; Maxillary Diseases; Embolization, Therapeutic
PubMed: 38867285
DOI: 10.1186/s13000-024-01505-1 -
BMC Complementary Medicine and Therapies Jun 2024This study was conducted to determine the effect of music on the pain, anxiety, and comfort levels of patients who underwent bone marrow aspiration and biopsy. (Clinical Trial)
Clinical Trial
AIM
This study was conducted to determine the effect of music on the pain, anxiety, and comfort levels of patients who underwent bone marrow aspiration and biopsy.
METHODS
This study was conducted on patients with hematological malignancies. Music was used with the intervention group. Patients' pain, anxiety, and comfort levels were measured. In addition, qualitative data were obtained through in-depth interviews with patients.
RESULTS
A significant difference (p < 0.05) was found between the experimental and control groups regarding pain, comfort and anxiety levels following the application of music. It was found that there was a negative correlation between comfort and pain (r=-0.442 p < 0.001) and between comfort and anxiety (r=-0.544 p < 0.001). As a result of qualitative interviews, patients mentioned the relaxing effect of music and the reduction of anxiety and pain levels. They also stated that music can be utilized as an alternative method.
CONCLUSION
According to the results of the present study, music reduced the pain and anxiety levels of the patients in bone marrow aspiration and biopsy and increased their comfort levels. We can say that music can be used in the clinic as a non-pharmacological method for pain, anxiety and comfort.
CLINICAL TRIALS NUMBER
NCT05895357 (Date:08/06/2023).
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Young Adult; Anxiety; Biopsy; Bone Marrow; Hematologic Neoplasms; Music Therapy; Pain; Pain Management; Pain Measurement; Patient Comfort; Turkey
PubMed: 38867235
DOI: 10.1186/s12906-024-04531-0 -
Scientific Reports Jun 2024This study proposes the beta-emitting radioisotope Pr as a promising candidate for palliative treatment of metastatic bone pain due to its desirable physical decay...
This study proposes the beta-emitting radioisotope Pr as a promising candidate for palliative treatment of metastatic bone pain due to its desirable physical decay characteristics. An optimized process was developed for the production and purification of non-carrier-added Pr using a medium flux research reactor. Calculations were performed to determine the optimal irradiation time and cooling period for irradiating 1 mg of natural cerium oxide to indirectly produce Pr through the decay of Ce. Following irradiation and cooling, extraction chromatography was employed to efficiently isolate Pr from the irradiated target material. A column containing Ln-resin was used along with nitric acid as the mobile phase and an optional oxidation step with NaBrO/ascorbic acid to separate Pr from impurities such as Ce and Ce. Radionuclidic purity of over 99.995% was achieved as confirmed through gamma spectroscopy, demonstrating effective separation of Pr. Additional quality control analyses established the chemical and radiochemical purity of the purified Pr nitrate product. With a half-life of 13.6 days and maximum beta energy of 0.937 MeV, Pr exhibits favorable properties for palliative bone pain therapy. This study therefore provides a viable method for producing high-purity Pr through the optimized irradiation and purification processes described. Further investigation is warranted to explore potential clinical applications of Pr for palliation of metastatic bone cancer pain.
Topics: Bone Neoplasms; Palliative Care; Humans; Cancer Pain; Radiopharmaceuticals; Radioisotopes
PubMed: 38866894
DOI: 10.1038/s41598-024-64321-z -
Scientific Reports Jun 2024While better management of loco-regional prostate cancer (PC) has greatly improved survival, advanced PC remains a major cause of cancer deaths. Identification of novel...
While better management of loco-regional prostate cancer (PC) has greatly improved survival, advanced PC remains a major cause of cancer deaths. Identification of novel targetable pathways that contribute to tumor progression in PC could open new therapeutic options. The di-ganglioside GD2 is a target of FDA-approved antibody therapies in neuroblastoma, but the role of GD2 in PC is unexplored. Here, we show that GD2 is expressed in a small subpopulation of PC cells in a subset of patients and a higher proportion of metastatic tumors. Variable levels of cell surface GD2 expression were seen on many PC cell lines, and the expression was highly upregulated by experimental induction of lineage progression or enzalutamide resistance in CRPC cell models. GD2 cell fraction was enriched upon growth of PC cells as tumorspheres and GD2 fraction was enriched in tumorsphere-forming ability. CRISPR-Cas9 knockout (KO) of the rate-limiting GD2 biosynthetic enzyme GD3 Synthase (GD3S) in GD2 CRPC cell models markedly impaired the in vitro oncogenic traits and growth as bone-implanted xenograft tumors and reduced the cancer stem cell and epithelial-mesenchymal transition marker expression. Our results support the potential role of GD3S and its product GD2 in promoting PC tumorigenesis by maintaining cancer stem cells and suggest the potential for GD2 targeting in advanced PC.
Topics: Male; Humans; Neoplastic Stem Cells; Sialyltransferases; Animals; Cell Line, Tumor; Gangliosides; Mice; Carcinogenesis; Prostatic Neoplasms; Phenylthiohydantoin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Benzamides; Nitriles
PubMed: 38866755
DOI: 10.1038/s41598-024-60052-3 -
International Journal of Surgery Case... Jul 2024Cystic lesions in long bones are the radiological presentation of various bone pathologies, they can easily be misdiagnosed and thus mistreated; treatment varies from...
INTRODUCTION
Cystic lesions in long bones are the radiological presentation of various bone pathologies, they can easily be misdiagnosed and thus mistreated; treatment varies from observation to aggressive surgical interventions based on the nature and characteristics of the lesion.
CASE PRESENTATION
A 25-year-old male had a twisting injury to his ankle and his radiographs showed a cystic lesion in the distal tibia that was asymptomatic until he injured his ankle. he had persistent pain since then. and after conservative methods failure, a two-stage surgical intervention was done; first, we curetted the lesion and filled it with antibiotics cement; then the cement was removed with autologous bone grafting. The patient eventually healed and returned to his normal activity level.
DISCUSSION
Brodie's abscess has a similar radiological appearance to other bone neoplasms and tumor-like lesions. Clinically, it is minimally symptomatic, and often initially misdiagnosed; surgical treatment is very effective, but it depends on the size, location, and aggressiveness of the lesion; the goal is to eliminate the infection, refill the residual gap, and restore the normal function, especially in weight-bearing bones.
CONCLUSION
Brodie's abscess is a hideous lesion that is hard to diagnose. It could mimic other tumor-like lesions. However, applying bone cement and a second stage of bone grafting might help maximize the treatment efficiency.
PubMed: 38865946
DOI: 10.1016/j.ijscr.2024.109865 -
Revista Da Associacao Medica Brasileira... 2024
-
Diagnostic Pathology Jun 2024Osteosarcoma is a bone tumor that is characterized by high malignancy and a high mortality rate, and that originates from primitive osteoblastic mesenchymal cells and is...
BACKGROUND
Osteosarcoma is a bone tumor that is characterized by high malignancy and a high mortality rate, and that originates from primitive osteoblastic mesenchymal cells and is most common in rapidly growing long bones. PSMD14, also known as RPN11 or POH1, is a member of the JAMM isopeptidase family, which is able to remove the substrate protein ubiquitination label, thereby regulating the stability and function of the substrate protein. In this study, we explored the expression and potential biological significance of the PSMD14 deubiquitinating enzyme in osteosarcoma.
METHODS
Immunohistochemical methods were used to detect the expression of PSMD14 in biopsies of 91 osteosarcoma patients, and the specimens were classified into high and low PSMD14 expression groups. The correlation between PSMD14 expression and clinical indicators and prognosis was compared.SiRNA was used to downregulate PSMD14 in two osteosarcoma cell lines (HOS and SJSA-1), and the effects of downregulation of PSMD14 on the viability, proliferation, and invasion ability of osteosarcoma cells were analyzed.
RESULTS
We identified significant differences in recurrence, metastasis, and survival time of the osteosarcoma patients on the basis of PSMD14 expression. High expression of PSMD14 in osteosarcoma patients was associated with a low survival rate and high risk of metastasis and recurrence. Down-regulation of PSMD14 inhibited the viability, proliferation, and invasiveness of osteosarcoma cell lines.
CONCLUSIONS
PSMD14 may be a new prognostic marker and therapeutic target for osteosarcoma.
Topics: Osteosarcoma; Humans; Bone Neoplasms; Male; Biomarkers, Tumor; Female; Prognosis; Cell Line, Tumor; Adult; Cell Proliferation; Proteasome Endopeptidase Complex; Adolescent; Young Adult; Middle Aged; Neoplasm Invasiveness; Trans-Activators
PubMed: 38863002
DOI: 10.1186/s13000-024-01489-y -
Scientific Reports Jun 2024Bone-modifying agents (BMA) are extensively used in treating patients with prostate cancer with bone metastases. However, this increases the risk of medication-related...
Bone-modifying agents (BMA) are extensively used in treating patients with prostate cancer with bone metastases. However, this increases the risk of medication-related osteonecrosis of the jaw (MRONJ). The safety of long-term BMA administration in clinical practice remains unclear. We aimed to determine the cumulative incidence and risk factors of MRONJ. One hundred and seventy-nine patients with prostate cancer with bone metastases treated with BMA at our institution since 2008 were included in this study. Twenty-seven patients (15%) had MRONJ during the follow-up period (median, 19 months; interquartile range, 9-43 months). The 2-year, 5-year, and 10-year cumulative MRONJ incidence rates were 18%, 27%, and 61%, respectively. Multivariate analysis identified denosumab use as a risk factor for MRONJ, compared with zoledronic acid use (HR 4.64, 95% CI 1.93-11.1). Additionally, BMA use at longer than one-month intervals was associated with a lower risk of MRONJ (HR 0.08, 95% CI 0.01-0.64). Furthermore, six or more bone metastases (HR 3.65, 95% CI 1.13-11.7) and diabetes mellitus (HR 5.07, 95% CI 1.68-15.2) were risk factors for stage 2 or more severe MRONJ. MRONJ should be considered during long-term BMA administration in prostate cancer patients with bone metastases.
Topics: Humans; Male; Prostatic Neoplasms; Risk Factors; Aged; Incidence; Bisphosphonate-Associated Osteonecrosis of the Jaw; Denosumab; Bone Neoplasms; Bone Density Conservation Agents; Middle Aged; Zoledronic Acid; Aged, 80 and over; Retrospective Studies
PubMed: 38862617
DOI: 10.1038/s41598-024-64440-7 -
Scientific Reports Jun 2024This study aimed to determine an immune-related RNA signature as a prognostic marker, in this study, we developed a risk score model for predicting the prognosis of...
This study aimed to determine an immune-related RNA signature as a prognostic marker, in this study, we developed a risk score model for predicting the prognosis of osteosarcoma metastasis. We first downloaded the clinical information and expression data of osteosarcoma samples from the UCSC Xena and GEO databases, of which the former was the training set and the latter was the validation set. Immune infiltration was assessed using the ssGSEA and ESTIMATE algorithms, and the osteosarcoma samples were divided into the Immunity_L and Immunity_H groups. Then, eleven RNAs were identified as the optimal prognostic RNA signatures using LASSO Cox regression analysis for establishing a risk score (RS) model. Kaplan-Meier approach indicated the high-risk group exhibited a shorter survival. Furthermore, we analyzed the tumor metastasis, age, and RS model status were determined to be independent clinical prognostic factors using Cox regression analysis. Decision curve analysis (DCA) indicated that the prognostic factor + RS model had the best net benefit. Finally, nine tumor-infiltrating immune cells (TIICs) showed significant differences in abundance between high- and low-risk groups via CIBERSORT deconvolution algorithm. In conclusion, the immune-related eleven-RNA signature be could served as a potential prognostic biomarker for osteosarcoma metastasis.
Topics: Osteosarcoma; Humans; Prognosis; Bone Neoplasms; Biomarkers, Tumor; Female; Male; Gene Expression Regulation, Neoplastic; Neoplasm Metastasis; Kaplan-Meier Estimate; Gene Expression Profiling; Transcriptome; Proportional Hazards Models; Risk Factors; Algorithms
PubMed: 38862526
DOI: 10.1038/s41598-024-54292-6 -
Acta Ortopedica Mexicana 2024different variables have been associated with a worse prognosis of patients with osteosarcoma (OS), highlighting tumor size, location in the axial skeleton and the...
INTRODUCTION
different variables have been associated with a worse prognosis of patients with osteosarcoma (OS), highlighting tumor size, location in the axial skeleton and the presence of metastases. The objective of this study is to analyze the prognostic impact of diagnostic delay in osteosarcoma in adults in the Mexican population in a center specialized in sarcomas.
MATERIAL AND METHODS
retrospective cohort study from January 1, 2005, to December 31, 2016, 96 patients over 21 years of age with a diagnosis of osteosarcoma were analyzed.
RESULTS
the median time to diagnosis from the onset of symptoms was six months (range: 2-36). This variable was dichotomized by applying the operator-dependent curve (ROC) analysis and we determined a cut-off value greater than five months, with an area under the curve (AUC) = 0.93 [95% CI 0.86-0.97], sensitivity 93.2% and specificity 94.6%.
CONCLUSION
time until diagnosis is a critical factor in the survival of adult patients with osteosarcoma, highlighting its influence on disease progression and the appearance of metastasis. The correlation between diagnostic delay and an unfavorable prognosis reinforces the need for rapid and efficient evaluation in suspected cases of osteosarcoma.
Topics: Humans; Osteosarcoma; Retrospective Studies; Male; Adult; Female; Bone Neoplasms; Delayed Diagnosis; Prognosis; Middle Aged; Young Adult; Aged; Mexico; Time Factors; Sensitivity and Specificity; Cohort Studies; Disease Progression; ROC Curve
PubMed: 38862146
DOI: 10.35366/115811